Liberia vs Zimbabwe: Statin use vs. average non-HDL cholesterol levels
Liberia
2.8
in 2018
Zimbabwe
2.8
in 2018
Liberia rank
163rd
Zimbabwe rank
163rd
Statin use vs. average non-HDL cholesterol levels over time
- Liberia
- Zimbabwe
How they compare
Liberia currently reports 2.8 against 2.8 in Zimbabwe, a difference of 0.
The two have swapped places 3 times across 39 shared years of data; in 1980 it was Liberia ahead.
Liberia ranks 163rd and Zimbabwe ranks 163rd of 191 countries.
Across the 4 decades both report, Liberia averaged higher in 1 and Zimbabwe in 2.
Head to head by decade
| Decade | Liberia | Zimbabwe | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 2.64 | 2.63 | 0.01 | Liberia |
| 1990s | 2.78 | 2.78 | 0 | — |
| 2000s | 2.74 | 2.86 | 0.12 | Zimbabwe |
| 2010s | 2.8 | 2.88 | 0.0778 | Zimbabwe |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher statin use vs. average non-hdl cholesterol levels, Liberia or Zimbabwe?
- Liberia, at 2.8 against 2.8 in Zimbabwe as of 2018.
- What is the difference in statin use vs. average non-hdl cholesterol levels between Liberia and Zimbabwe?
- 0, with Liberia ahead.
- How many years of comparable data are there for Liberia and Zimbabwe?
- 39 years are reported by both, from 1980 to 2018.
- How do Liberia and Zimbabwe rank globally for statin use vs. average non-hdl cholesterol levels?
- Liberia ranks 163rd and Zimbabwe ranks 163rd of 191 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Statin use vs. average non-HDL cholesterol levels. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The use of statins in the population. This is compared to average non-HDL cholesterol levels, in mmol/L. Statins are a type of drug that reduce non-HDL cholesterol levels, and are used to treat and prevent cardiovascular diseases in people at heightened risk. Their usage is measured in Defined Daily Doses, per 1,000 people.